Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Despite enormous advances, management of multiple myeloma (MM) remains challenging. Multiple factors impact the decision to treat or which regimen to use at MM relapse/progression. Recent major randomized controlled trials (RCTs) showed widely varying progression-free survivals (PFS), ranging from a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chim, C S, Kumar, S K, Orlowski, R Z, Cook, G, Richardson, P G, Gertz, M A, Giralt, S, Mateos, M V, Leleu, X, Anderson, K C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808071/
https://www.ncbi.nlm.nih.gov/pubmed/29257139
http://dx.doi.org/10.1038/leu.2017.329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808071/
https://www.ncbi.nlm.nih.gov/pubmed/29257139
http://dx.doi.org/10.1038/leu.2017.329

Ejemplares similares